Kinevant Sciences
Biotechnology, 6200 Lookout Rd, New York, 80301, United States, 11-50 Employees
Who is KINEVANT SCIENCES
Kinevant Sciences is on a mission to transform the lives of people living with rare inflammatory diseases through high-impact medicine. Kine is a word from Ancient Greece meaning to move ...
Read More
-
Headquarters: 6200 Lookout Rd, New York, New York, 80301, United States
-
Date Founded: 2019
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 621511 |
Show More
Does something look wrong? Fix it. | View contact records from KINEVANT SCIENCES
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Kinevant Sciences
Answer: Kinevant Sciences's headquarters are located at 6200 Lookout Rd, New York, 80301, United States
Answer: Kinevant Sciences's official website is https://kinevant.com
Answer: Kinevant Sciences's revenue is $10 Million to $25 Million
Answer: Kinevant Sciences's SIC: 2834
Answer: Kinevant Sciences's NAICS: 621511
Answer: Kinevant Sciences has 11-50 employees
Answer: Kinevant Sciences is in Biotechnology
Answer: Kinevant Sciences contact info: Phone number: Website: https://kinevant.com
Answer: Kinevant Sciences is on a mission to transform the lives of people living with rare inflammatory diseases through high-impact medicine. Kine is a word from Ancient Greece meaning to move or set in motion, which defines our purpose of moving safe and accessible therapeutics forward, so patients feel empowered to take back full control of their lives. Our approach combines patient-forward thinking, scientific rigor and clinical excellence to overcome some of the most deep-rooted barriers to treatment within underserved populations by delivering disease-modifying therapeutics that are safe, well tolerated and easily accessible. Our lead product candidate, namilumab, is an investigational monoclonal antibody being developed for treatment of sarcoidosis. Namilumab has the potential to address the underlying disease pathology by targeting GM-CSF, a key pro-inflammatory cytokine and growth factor implicated in the pathogenesis of sarcoidosis and other inflammatory disorders. Kinevant has initiated two actively enrolling clinical trials to investigate namilumab as a potential new treatment for sarcoidosis to significantly improve patients overall quality of life.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month